Analyst Ratings for Nektar Therapeutics (NKTR)
NKTR Rating Summary
NKTR Price Target Summary
- Highest: $20.00 (Brean Capital)
- Lowest: $5.00 (ThinkEquity)
- Average: $11.86
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$11.86 (+27.9%)
Avg. $ Target:
$11.86 (+27.9%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/15/2013 | Lazard Capital | New Coverage | Buy (N/A) |
15.00 (N/A) |
8.74 | 9.27 | 6.06% | Details |
| 11/12/2012 | Jefferies | Downgrade | Hold (Buy) |
8.00 (10.00) |
8.15 | 9.27 | 13.74% | Details |
| 5/24/2012 | Roth Capital | New Coverage | Buy (N/A) |
10.00 (N/A) |
6.97 | 9.27 | 33% | Details |
| 1/20/2012 | BofA/Merrill Lynch | Downgrade | Underperform (N/A) |
N/A (N/A) |
6.30 | 9.27 | 47.14% | Details |
| 1/17/2012 | ThinkEquity | Downgrade | Sell (N/A) |
5.00 (N/A) |
6.72 | 9.27 | 37.95% | Details |
| 5/17/2011 | Boenning & Scattergood | New Coverage | Outperform (N/A) |
N/A (N/A) |
9.95 | 9.27 | -6.83% | Details |
